The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia

NCT02577926 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

207

Enrollment

OTHER

Sponsor class

Conditions

Polycythemia Vera (PV)
Essential Thrombocythemia (ET)

Interventions

DRUG: Ruxolitinib
DRUG: BAT

Sponsor

RWTH Aachen University

Collaborators

[object Object]